Close

Cipla Medpro to market Teva’s pharmaceutical products in South Africa

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Cipla Medpro subsidiary Medpro Pharmaceutica has entered into an agreement with Teva Pharmaceuticals.

As part of the deal, Medpro will exclusively market Teva’s pharmaceutical product portfolio in South Africa.

Cipla Medpro CEO Paul Miller said: “This collaboration is highly complementary and aligns strongly with our philosophy of providing South Africans with access to a broader range of affordable medicines.

In South Africa, Teva will focus on the products in therapeutic areas such as oncology, central nervous system, women’s health, cardiovascular, ophthalmology, as well as on other specialty products.

“Teva will focus on the products in therapeutic areas such as oncology, central nervous system, women’s health, cardiovascular, ophthalmology, as well as on other specialty products.”

Cipla global CEO and managing director Subhanu Saxena said: “Cipla believes that the collaboration with Teva reaffirms its commitment to advancing healthcare for all South Africans.”

Teva Pharmaceuticals supplies its products in around 60 countries, while Cipla Medpro is said to be the third largest pharmaceutical company in South Africa.

In September, Cipla partnered with UK’s S&D Pharma to launch affordable, high-quality alternatives in the Czech Republic and Slovakia.

Under the deal, Cipla will introduce its respiratory product portfolio in both the countries, while S&D Pharma will look after the physical distribution of all products, including respiratory products.

Cipla produces around 2,000 products in 65 therapeutic categories. The company has reported around $1.7bn turnover in fiscal year 2013-2014, which supplies its products in around 170 countries.

Latest stories

Related stories

Tjoapack Expands Injectable Packaging Capabilities Globally

Increased Capabilities in the United States Tjoapack is finishing up...

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back